<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22957013</article-id><article-id pub-id-type="pmc">3434212</article-id><article-id pub-id-type="publisher-id">PONE-D-11-21671</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0041339</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Analysis Tools</subject><subj-group><subject>Transcriptomes</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Genomics</subject><subj-group><subject>Genome Analysis Tools</subject><subj-group><subject>Transcriptomes</subject></subj-group></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Monocytes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Anatomy and Physiology</subject><subj-group><subject>Integrative Physiology</subject><subject>Renal System</subject></subj-group></subj-group><subj-group><subject>Cardiovascular</subject><subj-group><subject>Atherosclerosis</subject><subject>Heart Failure</subject></subj-group></subj-group><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Monocytes</subject></subj-group></subj-group></subj-group><subj-group><subject>Critical Care and Emergency Medicine</subject><subj-group><subject>Acute Renal Failure</subject></subj-group></subj-group><subj-group><subject>Nephrology</subject><subj-group><subject>Chronic Kidney Disease</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Short-Term Erythropoietin Treatment Does Not Substantially Modulate Monocyte Transcriptomes of Patients with Combined Heart and Renal Failure</article-title><alt-title alt-title-type="running-head">Monocyte Transcriptomes in Cardiorenal Syndrome</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jie</surname><given-names>Kim E.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>van der Putten</surname><given-names>Karien</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wesseling</surname><given-names>Sebastiaan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Joles</surname><given-names>Jaap A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bergevoet</surname><given-names>Marloes W.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pepers-de Kort</surname><given-names>Floor</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Doevendans</surname><given-names>Pieter A.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yasui</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Verhaar</surname><given-names>Marianne C.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gaillard</surname><given-names>Carlo A.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Braam</surname><given-names>Branko</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref><xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Internal Medicine, Meander Medical Center Amersfoort, Amersfoort, The Netherlands</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Service XS B.V., Leiden, The Netherlands</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, Canada</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Department of Nephrology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands</addr-line>
</aff><aff id="aff8">
<label>8</label>
<addr-line>Department of Medicine, Division of Nephrology and Immunology, University of Alberta, Edmonton, Canada</addr-line>
</aff><aff id="aff9">
<label>9</label>
<addr-line>Department of Physiology, University of Alberta, Edmonton, Canada</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Langmann</surname><given-names>Thomas</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Center of Ophtalmology, Germany</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>branko.braam@ualberta.ca</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>FPdK is employed by ServiceXS BV and is co-author since she assisted strongly in the efficient processing of the ILLUMINA microarrays and in the basic analysis of the array data, for which regular service fees were paid to the company. Roche Pharmaceuticals provided an unrestricted grant to support the study. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: CG BB. Performed the experiments: KJ KvdP MB FPdK. Analyzed the data: KJ SW JAJ MB YY QL BB. Contributed reagents/materials/analysis tools: YY QL BB FPdK SW JAJ. Wrote the paper: KJ BB. Supervision of KJ KvdP MB: MCV CG BB. Critical review of the manuscript: PD MCV JAJ.</p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>5</day><month>9</month><year>2012</year></pub-date><volume>7</volume><issue>9</issue><elocation-id>e41339</elocation-id><history><date date-type="received"><day>27</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>25</day><month>6</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2012 Jie et al</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Jie et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Combined heart and renal failure is associated with high cardiovascular morbidity and mortality. Anti-oxidant and anti-inflammatory, non-hematopoietic effects of erythropoietin (EPO) treatment have been proposed. Monocytes may act as biosensors of the systemic environment. We hypothesized that monocyte transcriptomes of patients with cardiorenal syndrome (CRS) reflect the pathophysiology of the CRS and respond to short-term EPO treatment at a recommended dose for treatment of renal anemia.</p></sec><sec><title>Methods</title><p>Patients with CRS and anemia (n&#x0200a;=&#x0200a;18) included in the EPOCARES trial were matched to healthy controls (n&#x0200a;=&#x0200a;12). Patients were randomized to receive 50 IU/kg/week EPO or not. RNA from CD14<sup>+</sup>-monocytes was subjected to genome wide expression analysis (Illumina) at baseline and 18 days (3 EPO injections) after enrolment. Transcriptomes from patients were compared to healthy controls and effect of EPO treatment was evaluated within patients.</p></sec><sec><title>Results</title><p>In CRS patients, expression of 471 genes, including inflammation and oxidative stress related genes was different from healthy controls. Cluster analysis did not separate patients from healthy controls. The 6 patients with the highest hsCRP levels had more differentially expressed genes than the 6 patients with the lowest hsCRP levels. Analysis of the variation in log<sub>2</sub> ratios of all individual 18 patients indicated that 4 of the 18 patients were different from the controls, whereas the other 14 were quite similar. After short-term EPO treatment, every patient clustered to his or her own baseline transcriptome. Two week EPO administration only marginally affected expression profiles on average, however, individual gene responses were variable.</p></sec><sec><title>Conclusions</title><p>In stable, treated CRS patients with mild anemia, monocyte transcriptomes were modestly altered, and indicated imprints of inflammation and oxidative stress. EPO treatment with a fixed dose has hematopoietic effects, had no appreciable beneficial actions on monocyte transcription profiles, however, could also not be associated with undesirable transcriptional responses.</p></sec></abstract><funding-group><funding-statement>External funding for this study was obtained from the Dutch Heart Foundation, by the University Medical Center Utrecht (MD/PhD fellowship to KEJ) and from Roche Pharmaceuticals. BB was supported by a New Investigator Grant from the Heart and Stroke Foundation of Canada. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Patients suffering from chronic heart failure (CHF) and concomitant renal failure have increased cardiovascular morbidity and mortality <xref rid="pone.0041339-Hillege1" ref-type="bibr">[1]</xref>. Conversely, chronic kidney disease (CKD) patients have an increased risk for myocardial infarction with higher mortality compared to the general population <xref rid="pone.0041339-Foley1" ref-type="bibr">[2]</xref>. This condition in which combined cardiac and renal dysfunction aggravates failure of the individual organs has been described as the cardiorenal syndrome (CRS) <xref rid="pone.0041339-Bongartz1" ref-type="bibr">[3]</xref>. In this paper, CRS is defined as the combination of CHF and CKD. Among the pathways involved in the pathogenesis of CRS are oxidative stress, inflammation, the renin-angiotensin system (RAS) and the sympathetic nervous system (SNS), the cardiorenal connectors <xref rid="pone.0041339-Bongartz1" ref-type="bibr">[3]</xref>.</p><p>Anemia is a well-recognized problem in chronic renal disease. The pathophysiology of renal anemia includes an absolute and/or relative deficiency to erythropoietin (EPO) and a reduced sensitivity to EPO of red-cell lineages. Regarding the former, analogues of the human EPO are available to increase EPO levels. Regarding the latter, transferrin receptor-bound polymeric IgA1 was recently identified as an important modulator of the bone marrow response to EPO <xref rid="pone.0041339-Coulon1" ref-type="bibr">[4]</xref>. Besides the cells involved in erythropoiesis, a number of other cells involved in cardiovascular disease have been shown to express EPO receptors (reviewed in <xref rid="pone.0041339-Jie1" ref-type="bibr">[5]</xref>) including monocytes <xref rid="pone.0041339-Lisowska1" ref-type="bibr">[6]</xref>.</p><p>Anemia can aggravate heart and renal failure and is associated with worse outcome in CHF <xref rid="pone.0041339-Groenveld1" ref-type="bibr">[7]</xref> and CKD <xref rid="pone.0041339-Sarnak1" ref-type="bibr">[8]</xref>. EPO can be used to treat renal anemia, however, normalization of hemoglobin (Hgb) in CKD patients is not associated with improved cardiovascular outcome <xref rid="pone.0041339-Drueke1" ref-type="bibr">[9]</xref>, <xref rid="pone.0041339-Pfeffer1" ref-type="bibr">[10]</xref>, <xref rid="pone.0041339-Singh1" ref-type="bibr">[11]</xref>. In contrast, high EPO doses and the inability to reach target Hgb seem to be associated with adverse outcome <xref rid="pone.0041339-Szczech1" ref-type="bibr">[12]</xref>. EPO also has non-hematopoietic, anti-inflammatory and anti-oxidative effects on kidneys, brain, heart and vasculature <xref rid="pone.0041339-Chang1" ref-type="bibr">[13]</xref>, <xref rid="pone.0041339-Parsa1" ref-type="bibr">[14]</xref>. Nonetheless, not all reports are equivocal, and undesirable actions such as oxidative stress have also been reported <xref rid="pone.0041339-Jie1" ref-type="bibr">[5]</xref>.</p><p>Among several other circulating cells, monocytes can be used as sensors for direct EPO effects on these cells or for indirect actions of EPO by affecting the internal environment. Monocytes have previously been shown to be able to serve as biosensors to detect changes in the systemic environment <xref rid="pone.0041339-Ardigo1" ref-type="bibr">[15]</xref> and to evaluate the response to treatment <xref rid="pone.0041339-Chon1" ref-type="bibr">[16]</xref>, <xref rid="pone.0041339-WibautBerlaimont1" ref-type="bibr">[17]</xref>. In addition, monocytes are key players in the initiation and progression of atherosclerosis. Monocytes have shown to be sensitive to several of the cardiorenal connectors, such as cytokines and angiotensin II <xref rid="pone.0041339-AbdAlla1" ref-type="bibr">[18]</xref>, <xref rid="pone.0041339-Sprague1" ref-type="bibr">[19]</xref>. We have recently described that monocytes from CKD patients display increased expression of genes coding for suppressors of cytokine signaling proteins <xref rid="pone.0041339-Rastmanesh1" ref-type="bibr">[20]</xref>, <xref rid="pone.0041339-Rastmanesh2" ref-type="bibr">[21]</xref>. Monocyte transcriptomes also correlated with collateral artery formation in patients with coronary artery disease <xref rid="pone.0041339-Meier1" ref-type="bibr">[22]</xref>.</p><p>We have previously shown that short-term, low dose EPO treatment increases erythropoiesis as detected by increased reticulocyte counts <xref rid="pone.0041339-vanderPutten2" ref-type="bibr">[24]</xref>. In the present study, it was investigated whether monocyte gene expression profiles of cardiorenal patients reflect the altered systemic environment in CRS and are responsive to short-term, low-dose EPO treatment. First, we explored whether monocytes of CRS patients indeed display altered gene expression profiles compared to healthy controls. Moreover, we investigated whether short-term EPO treatment affects monocyte gene transcription. Since EPO might have undesirable effects, both potentially beneficial effects of EPO, such as induction of anti-inflammatory and anti-oxidant genes and potential detrimental effects on monocyte transcriptomes were investigated.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>The present study is part of the EPOCARES trial (ClinicalTrials.gov, NCT00356733), in which CRS patients on regular treatment and standardized iron supplementation were randomized to receive fixed dose subcutaneous EPO treatment or no EPO treatment. Details of the study design have previously been described <xref rid="pone.0041339-vanderPutten1" ref-type="bibr">[23]</xref>, <xref rid="pone.0041339-vanderPutten2" ref-type="bibr">[24]</xref>. Matched for age and gender, we selected 18 patients with mild anemia (10.3&#x02013;11.9 g/dl in women and 10.3&#x02013;12.6 g/dl in men), moderate renal failure (estimated creatinine clearance 20&#x02013;70 ml/min calculated by Cockcroft-Gault formula) and CHF. CHF was defined as New York Heart Association class II-IV, based on symptoms, signs and objective abnormality on echocardiography <xref rid="pone.0041339-Dickstein1" ref-type="bibr">[25]</xref>. Patients were included with reduced ejection fraction (&#x0003c;50%) or left ventricular end diastolic volume index &#x0003c;97 ml/m<sup>2</sup> with evidence of diastolic left ventricular dysfunction <xref rid="pone.0041339-Paulus1" ref-type="bibr">[26]</xref>. The medical ethics committee of the Univ. Medical Center Utrecht, The Netherlands approved the protocol and all patients gave their written informed consent. All procedures were in accordance with the Helsinki Declaration.</p><p>After enrolment, 12 out of 18 patients were randomized to receive a low dose of Epoetin-&#x003b2; therapy (50 IU/kg/wk; Neorecormon, Roche Pharmaceuticals). Dosages of EPO used in cardio- and cerebro-protection are higher than the dosages normally used for the treatment of renal anemia. It should also be remarked, that despite the desire to study higher doses of EPO in this setting, this would not be justifiable, given the data that is out there to suggest that the higher dosages may be associated unwanted cardiovascular effects <xref rid="pone.0041339-Drueke1" ref-type="bibr">[9]</xref>, <xref rid="pone.0041339-Singh1" ref-type="bibr">[11]</xref>, <xref rid="pone.0041339-Pfeffer2" ref-type="bibr">[27]</xref>. Biochemical analysis and monocyte isolation for gene expression analyses were performed at baseline and after 18 days of EPO treatment (i.e. after 3 EPO injections), prior to the expected rise in Hgb level. Twelve healthy age- and gender-matched persons served as baseline controls.</p></sec><sec id="s2b"><title>Sample collection and microarray procedures</title><p>Peripheral blood was collected from patients and healthy controls in EDTA containing tubes after 30 minutes in a resting position. Blood was kept on ice. Within 3 hours of blood withdrawal, CD14<sup>+</sup>-monocytes were positively isolated with the use of immunomagnetic beads (Invitrogen, CA). The purity of the isolated monocyte population was on average 90% as determined by CD14<sup>+</sup>-staining on flow cytometry analysis.</p><p>mRNA was isolated from cell collections using Trizol reagent (Invitrogen/Gibco, CA) according to the manufacturer's instruction. Subsequently, mRNA was purified with NucleoSpin&#x000ae; RNAII (Macherey-Nagel, D&#x000fc;ren, Germany) and samples were sent to ServiceXS (Leiden, The Netherlands) for further microarray processing. In brief, quality and integrity of RNA was checked by lab-on-chip technology (Bioanalyzer Agilent, CA). Subsequently, Illumina TotalPrep RNA Amplificationkit (Applied Biosystems/Ambion, TX) was used to create double-stranded cDNA from 500 ng total RNA. After cDNA purification, in vitro transcription reaction resulted in aRNA, which was also purified. Amplified biotinylated aRNA was finally randomly hybridized to HumanRef-8 V3.0 Expression BeadChips (Illumina, CA), followed by scanning for raw gene expression intensities on Illumina's BeadArray scanner.</p></sec><sec id="s2c"><title>Validation of gene array results by real-time quantitative polymerase chain reaction (qPCR)</title><p>Monocyte cDNA samples from all patients before and after 18 days EPO treatment and from healthy controls were subjected to real-time qPCR by BioMark dynamic array technology (Fluidigm, CA), performed at ServiceXS. The cDNA samples were exposed to specific target amplification, using PreAmp Master Mix and Gene Expression Assays (Taqman; Applied Biosystems, TX) for IL8, FOS, EGR1, CX3CR1, ADRB2, EPO-R and housekeeping genes GAPDH, 18S, &#x003b2;-Actin and RPL13a. They were subjected to a BioMark dynamic array for determination of Ct-values. Each gene was measured in triplicate for each sample. The default Taqman PCR protocol was used with an annealing temperature of 60&#x000b0;C and a total of 35 cycles of PCR.</p></sec><sec id="s2d"><title>Statistical analyses</title><p>Clinical characteristics are presented as mean&#x000b1;standard deviation or median (interquartile range) for respectively normally and not normally distributed data. Analysis between groups for statistically significant differences was performed by Student's t-test, Mann-Whitney U test or paired analysis when appropriate. P-values&#x0003c;0.05 were considered significant.</p><p>For microarray data analysis, individual bead outliers were removed from raw bead data if signal intensity was higher or lower than median intensity plus or minus 2&#x000d7; median absolute deviation respectively (T4Illumina, software developed by the authors). The transcript level of a gene in each sample was considered present when the average raw intensity of the gene was significantly higher than negative controls from the same BeadArray (t-test; T4Illumina). Genes were significantly present (transcriptionally active) in a group when present in at least 8 or 13 out of 12 or 18, respectively (based on group size by Z-test, SigmaStat). After normalization procedure (Log<sub>2</sub>-Quantile; FlexArray version 1.6 <xref rid="pone.0041339-Blazejczyk1" ref-type="bibr">[28]</xref>), differential expression of a gene between two groups was tested by unpaired Cyber t-test for the comparison between groups at baseline and paired t-test for the comparison between patients at baseline and after two weeks of EPO treatment <xref rid="pone.0041339-Baldi1" ref-type="bibr">[29]</xref>. A. P-value&#x0003c;0.05 was considered significant. To investigate the effects of EOP, genes that were significantly differentially expressed were analyzed by hierarchical clustering, with Euclidean distance as a similarity measure and clustering was based on average-linkage correlation (Multi-experiment-Viewer, MeV, version 4.8 <xref rid="pone.0041339-Saeed1" ref-type="bibr">[30]</xref>). To construct the heat-map, relative expression levels for each gene and each individual were calculated as a ratio between the actual signal for that gene and the average signal for that gene at baseline. Common oxidative stress-, inflammation- and RAS-related genes were specifically addressed to search for differences between healthy controls and patients, and for the effect of short-term EPO treatment in patients. Moreover, because of the relevance of inflammation for monocyte function, we subdivided the group of patients into three tertiles of CRP levels and investigated whether CRP levels were associated with different transcriptomes at baseline by comparing the lowest and highest tertiles. Finally, variation in the normally distributed log<sub>2</sub> ratios of each of the patients' baseline datasets was individually compared to variation of the control datasets. This provided further insight in the homogeneity of the baselines samples.</p><p>For real-time qPCR analysis, software version 2.0.6 was used for Ct determination from the reaction chambers on the array. Linear baseline correction was applied and the Ct threshold method selected was &#x02018;Auto (Global)&#x02019;. Average Ct values per gene for each sample were calculated for data that passed amplification curve quality thresholds (default value 0.65). GAPDH served as housekeeping gene, since this gene was considered most stable when comparing 18S, &#x003b2;-Actin, RPL13a and GAPDH in both NormFinder and GeNorm. Normalized gene expression (Ct gene of interest&#x02013;Ct GAPDH; &#x00394;Ct) was related to normalized gene expression in the reference group (&#x00394;&#x00394;Ct). Fold changes were calculated by 2<sup>&#x02212;&#x00394;&#x00394;CT</sup>
<xref rid="pone.0041339-Rastmanesh1" ref-type="bibr">[20]</xref>, <xref rid="pone.0041339-Rastmanesh2" ref-type="bibr">[21]</xref>. Gene expression differences between healthy controls and patients, and effects of EPO treatment were tested by Student's t-test and paired analyses respectively. P-value&#x0003c;0.05 was considered significant.</p></sec><sec id="s2e"><title>Accession codes</title><p>The data discussed in this publication have been deposited in MIAME compliant NCBI's Gene Expression Omnibus <xref rid="pone.0041339-Edgar1" ref-type="bibr">[31]</xref> and are accessible through GEO Series accession number GSE17582 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17582">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17582</ext-link>).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Study population characteristics</title><p>Baseline characteristics of patients with CRS and anemia and age- and gender-matched controls are described in <xref ref-type="table" rid="pone-0041339-t001">table 1</xref>. After the baseline measurement, twelve out of 18 patients were started on EPO treatment. After 18 days, Hgb was not increased significantly compared to baseline (delta Hgb 0.5&#x000b1;1.0 g/dl in EPO-treated group vs. &#x02212;0.4&#x000b1;1.0 g/dl in non EPO-treated group; p&#x0200a;=&#x0200a;0.133). The short-term EPO treatment did trigger the hematopoietic system as indicated by increased reticulocyte counts (0.05&#x000b1;0.02 vs. 0.07&#x000b1;0.02&#x000d7;10e12/l; p&#x0003c;0.001). Whole blood mononuclear cell (MNC) counts were not different in patients compared to healthy controls (6.3(3.2) vs. 5.1(2.0)&#x000d7;10<sup>6</sup> MNC/ml whole blood; p&#x0200a;=&#x0200a;0.215) and remained unchanged after short-term EPO treatment (6.3(3.2) vs. 6.8(2.7)&#x000d7;10<sup>6</sup> MNC/ml whole blood; p&#x0200a;=&#x0200a;0.420).</p><table-wrap id="pone-0041339-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0041339.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics.</title></caption><alternatives><graphic id="pone-0041339-t001-1" xlink:href="pone.0041339.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Healthy controls</td><td align="left" rowspan="1" colspan="1">Patients</td><td align="left" rowspan="1" colspan="1">P-value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;12)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;18)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">68&#x000b1;12</td><td align="left" rowspan="1" colspan="1">70&#x000b1;11</td><td align="left" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" rowspan="1" colspan="1">Male gender (%)</td><td align="left" rowspan="1" colspan="1">8 (67%)</td><td align="left" rowspan="1" colspan="1">12 (67%)</td><td align="left" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">23.7&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">26.7&#x000b1;4.5</td><td align="left" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated creatinine clearance (ml/min)</td><td align="left" rowspan="1" colspan="1">69&#x000b1;19</td><td align="left" rowspan="1" colspan="1">36&#x000b1;11</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td align="left" rowspan="1" colspan="1">14.0&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">11.8&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.08&#x000b1;1.26</td><td align="left" rowspan="1" colspan="1">4.39&#x000b1;1.52</td><td align="left" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.39&#x000b1;0.37</td><td align="left" rowspan="1" colspan="1">1.21&#x000b1;0.29</td><td align="left" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL (mmol/l)</td><td align="left" rowspan="1" colspan="1">3.31&#x000b1;1.07</td><td align="left" rowspan="1" colspan="1">2.38&#x000b1;1.17</td><td align="left" rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mmol/l)</td><td align="left" rowspan="1" colspan="1">0.84&#x000b1;0.50</td><td align="left" rowspan="1" colspan="1">1.75&#x000b1;1.70</td><td align="left" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" rowspan="1" colspan="1">hsCRP (mg/l)</td><td align="left" rowspan="1" colspan="1">1.0 (0.8)</td><td align="left" rowspan="1" colspan="1">4.0 (8.0)</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">46&#x000b1;4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">129&#x000b1;24</td><td align="left" rowspan="1" colspan="1">129&#x000b1;18</td><td align="left" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">81&#x000b1;7</td><td align="left" rowspan="1" colspan="1">70&#x000b1;8</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes Mellitus (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">6 (33%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoking (%)</td><td align="left" rowspan="1" colspan="1">2 (17%)</td><td align="left" rowspan="1" colspan="1">3 (17%)</td><td align="left" rowspan="1" colspan="1">N.S.</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Medication</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- Acetylsalicylic acid (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">8 (44%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- Statin (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">10 (56%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- Angiotensin blockade (ACEi/ARB) (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">16 (89%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">-&#x003b2;-blockade (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">13 (72%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- Spironolactone (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">4 (22%)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>Values are expressed as mean &#x000b1; SD, number (percentage) or median (interquartile range).</p></fn><fn id="nt102"><p>hsCRP: high sensitive C-reactive protein; ACEi: angiotension-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; N.S. not significant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Erythropoietin receptor expression on monocytes</title><p>All monocyte samples showed a significant gene expression of the EPO receptor (EPO-R), reflected by Ct values of 18.0&#x000b1;0.5 on real-time qPCR. Slightly higher EPO-R gene expression was found in patients compared to controls (fold change 1.2; p&#x0200a;=&#x0200a;0.05). EPO treatment for 18 days did not significantly alter EPO-R expression (fold change 1.0).</p></sec><sec id="s3c"><title>Monocyte gene expression profile in cardiorenal syndrome patients compared to healthy controls</title><sec id="s3c1"><title>Global gene expression profile changes, hierarchical clustering</title><p>We compared monocyte gene expression profiles of CRS patients (n&#x0200a;=&#x0200a;18) and healthy controls (n&#x0200a;=&#x0200a;12) at baseline. Out of 25,528 genes explored, signals of 12,165 exceeded background in at least one of the two groups; 471 genes were differentially expressed in CRS patients vs. healthy controls (p-value&#x0003c;0.05; 1.8% of total assessed genes). Correction for multiple testing, for example by applying FDR, was not performed because of the very small sample size. Fold changes were low, ranging from 0.3&#x02013;1.7. Cluster analysis of differentially expressed genes did not separate patients from controls. Clustering of genes could also not be explained by gender or age of the investigated subjects.</p></sec><sec id="s3c2"><title>Specific gene expression changes</title><p>In CRS patients, 214 genes displayed increased and 257 decreased expression compared to healthy controls. <xref ref-type="table" rid="pone-0041339-t002">Table 2</xref> gives an overview of the 15 most induced and downregulated genes for this comparison. A table with all genes with changed expression can be found in table S1. Patients showed lower expression of the transcription factors EGR1 and FOS. Furthermore, patients showed decreased expression of hemoglobin-related genes HBA2 and HBB compared to healthy controls. Additional experiments with extra washing steps of isolated monocyte samples suggest that expression of these two genes could possibly be attributed to reticulocyte contamination (data not shown).</p><table-wrap id="pone-0041339-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0041339.t002</object-id><label>Table 2</label><caption><title>Top 15 of induced and downregulated genes in CRS patients vs. healthy controls.</title></caption><alternatives><graphic id="pone-0041339-t002-2" xlink:href="pone.0041339.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="3" align="left" rowspan="1">UPREGULATED (ranked by descending fold change)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Accession Number</td><td align="left" rowspan="1" colspan="1">Symbol</td><td align="left" rowspan="1" colspan="1">Description</td><td align="left" rowspan="1" colspan="1">Fold change</td><td align="left" rowspan="1" colspan="1">P-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_018487.2</td><td align="left" rowspan="1" colspan="1">HCA112</td><td align="left" rowspan="1" colspan="1">Transmembrane protein 176A</td><td align="left" rowspan="1" colspan="1">1.695</td><td align="left" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_012456.1</td><td align="left" rowspan="1" colspan="1">TIMM10</td><td align="left" rowspan="1" colspan="1">Translocase of inner mitochondrial membrane 10 homolog</td><td align="left" rowspan="1" colspan="1">1.591</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_017911.1</td><td align="left" rowspan="1" colspan="1">C22ORF8</td><td align="left" rowspan="1" colspan="1">Family with sequence similarity 118, member A</td><td align="left" rowspan="1" colspan="1">1.582</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_001337.3</td><td align="left" rowspan="1" colspan="1">CX3CR1</td><td align="left" rowspan="1" colspan="1">Chemokine (C-X3-C motif) receptor 1</td><td align="left" rowspan="1" colspan="1">1.491</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_006498.2</td><td align="left" rowspan="1" colspan="1">LGALS2</td><td align="left" rowspan="1" colspan="1">Lectin, galactoside-binding, soluble, 2</td><td align="left" rowspan="1" colspan="1">1.464</td><td align="left" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_000024.3</td><td align="left" rowspan="1" colspan="1">ADRB2</td><td align="left" rowspan="1" colspan="1">Adrenergic, &#x003b2;2-, receptor, surface</td><td align="left" rowspan="1" colspan="1">1.446</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_005771.3</td><td align="left" rowspan="1" colspan="1">DHRS9</td><td align="left" rowspan="1" colspan="1">Dehydrogenase/reductase (SDR family) member 9</td><td align="left" rowspan="1" colspan="1">1.434</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_198097.1</td><td align="left" rowspan="1" colspan="1">C7ORF28B</td><td align="left" rowspan="1" colspan="1">Chromosome 7 open reading frame 28B</td><td align="left" rowspan="1" colspan="1">1.428</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_001343.1</td><td align="left" rowspan="1" colspan="1">DAB2</td><td align="left" rowspan="1" colspan="1">Disabled homolog 2, mitogen-responsive phosphoprotein</td><td align="left" rowspan="1" colspan="1">1.425</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_016021.2</td><td align="left" rowspan="1" colspan="1">UBE2J1</td><td align="left" rowspan="1" colspan="1">Ubiquitin-conjugating enzyme E2, J1</td><td align="left" rowspan="1" colspan="1">1.424</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_030670.1</td><td align="left" rowspan="1" colspan="1">PTPRO</td><td align="left" rowspan="1" colspan="1">Protein tyrosine phosphatase, receptor type, variant 6</td><td align="left" rowspan="1" colspan="1">1.385</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_001008566.1</td><td align="left" rowspan="1" colspan="1">TPST2</td><td align="left" rowspan="1" colspan="1">Tyrosylprotein sulfotransferase 2</td><td align="left" rowspan="1" colspan="1">1.379</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_030671.1</td><td align="left" rowspan="1" colspan="1">PTPRO</td><td align="left" rowspan="1" colspan="1">Protein tyrosine phosphatase, receptor type, variant 5</td><td align="left" rowspan="1" colspan="1">1.372</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NR_003038.1</td><td align="left" rowspan="1" colspan="1">SNHG5</td><td align="left" rowspan="1" colspan="1">Small nucleolar RNA host gene 5</td><td align="left" rowspan="1" colspan="1">1.359</td><td align="left" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_080914.1</td><td align="left" rowspan="1" colspan="1">ASGR2</td><td align="left" rowspan="1" colspan="1">asialoglycoprotein receptor 2</td><td align="left" rowspan="1" colspan="1">1.358</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td colspan="3" align="left" rowspan="1">
<bold>DOWNREGULATED (ranked by ascending fold change)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_000518.4</td><td align="left" rowspan="1" colspan="1">HBB</td><td align="left" rowspan="1" colspan="1">Hemoglobin, &#x003b2;</td><td align="left" rowspan="1" colspan="1">0.297</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_000517.3</td><td align="left" rowspan="1" colspan="1">HBA2</td><td align="left" rowspan="1" colspan="1">Hemoglobin, &#x003b1;2</td><td align="left" rowspan="1" colspan="1">0.376</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">XM_936120.1</td><td align="left" rowspan="1" colspan="1">HLA-DQA1</td><td align="left" rowspan="1" colspan="1">PREDICTED: major histocompatibility complex, class II</td><td align="left" rowspan="1" colspan="1">0.474</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_000584.2</td><td align="left" rowspan="1" colspan="1">IL8</td><td align="left" rowspan="1" colspan="1">Interleukin 8</td><td align="left" rowspan="1" colspan="1">0.584</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_005252.2</td><td align="left" rowspan="1" colspan="1">FOS</td><td align="left" rowspan="1" colspan="1">V-fos FBJ murine osteosarcoma viral oncogene homolog</td><td align="left" rowspan="1" colspan="1">0.606</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_006732.1</td><td align="left" rowspan="1" colspan="1">FOSB</td><td align="left" rowspan="1" colspan="1">FBJ murine osteosarcoma viral oncogene homolog B</td><td align="left" rowspan="1" colspan="1">0.608</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_001964.2</td><td align="left" rowspan="1" colspan="1">EGR1</td><td align="left" rowspan="1" colspan="1">Early growth response 1</td><td align="left" rowspan="1" colspan="1">0.646</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_004417.2</td><td align="left" rowspan="1" colspan="1">DUSP1</td><td align="left" rowspan="1" colspan="1">Dual specificity phosphatase 1</td><td align="left" rowspan="1" colspan="1">0.678</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_004666.1</td><td align="left" rowspan="1" colspan="1">VNN1</td><td align="left" rowspan="1" colspan="1">Vanin 1</td><td align="left" rowspan="1" colspan="1">0.680</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_024933.2</td><td align="left" rowspan="1" colspan="1">FLJ12056</td><td align="left" rowspan="1" colspan="1">Ankyrin repeat domain 53</td><td align="left" rowspan="1" colspan="1">0.692</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_005502.2</td><td align="left" rowspan="1" colspan="1">ABCA1</td><td align="left" rowspan="1" colspan="1">ATP-binding cassette, sub-family A, member 1</td><td align="left" rowspan="1" colspan="1">0.707</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_020152.2</td><td align="left" rowspan="1" colspan="1">C21ORF7</td><td align="left" rowspan="1" colspan="1">Chromosome 21 open reading frame 7</td><td align="left" rowspan="1" colspan="1">0.710</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_017933.3</td><td align="left" rowspan="1" colspan="1">FLJ20701</td><td align="left" rowspan="1" colspan="1">Phosphotyrosine interaction domain containing 1</td><td align="left" rowspan="1" colspan="1">0.725</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_002612.2</td><td align="left" rowspan="1" colspan="1">PDK4</td><td align="left" rowspan="1" colspan="1">Pyruvate dehydrogenase kinase, isozyme 4</td><td align="left" rowspan="1" colspan="1">0.736</td><td align="left" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NM_021732.1</td><td align="left" rowspan="1" colspan="1">AVPI1</td><td align="left" rowspan="1" colspan="1">Arginine vasopressin-induced 1</td><td align="left" rowspan="1" colspan="1">0.737</td><td align="left" rowspan="1" colspan="1">0.006</td></tr></tbody></table></alternatives></table-wrap><p>We specifically addressed whether inflammation and oxidative stress in CRS patients were reflected by monocyte gene expressions. Several interesting genes involved in inflammation (i.e. IL8, IL17, IL1RAP, CX3CR1, and several TLRs) and oxidative stress (i.e. DUSP1, GPX3, DHRS9) were indeed modulated in CRS patients (<xref ref-type="table" rid="pone-0041339-t003">table 3</xref>, and table S2 for the entire panel of genes). Remarkably, some of these genes exert pro- and others anti-stimulating activities. With regard to SNS, only ADRB2 was induced in patients. Differential expression of IL8, FOS, EGR1, CX3CR1 and ADRB2 was confirmed by qPCR (<xref ref-type="fig" rid="pone-0041339-g001">figure 1</xref>).</p><fig id="pone-0041339-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0041339.g001</object-id><label>Figure 1</label><caption><title>Validation of differentially expressed genes on microarray by quantitative polymerase chain reaction.</title><p>*P-value&#x0003c;0.05 for gene expression in patients at baseline vs. healthy controls as determined with qPCR technique; <sup>o</sup>P-value&#x0003c;0.05 for gene expression in patients at baseline vs. healthy controls as determined with microarray technique. ADRB2 adrenergic receptor, &#x003b2;2; CX3CR1 chemokine (C-X3-C motif) receptor 1; EGR1 early growth response 1; FOS FBJ murine osteosarcoma viral oncogene homolog; GPX3 glutathione peroxidase 3; IL8 interleukin 8; qPCR quantitative polymerase chain reaction.</p></caption><graphic xlink:href="pone.0041339.g001"/></fig><table-wrap id="pone-0041339-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0041339.t003</object-id><label>Table 3</label><caption><title>Induction and downregulation of oxidative stress and inflammation related genes in CRS patients vs. healthy controls.</title></caption><alternatives><graphic id="pone-0041339-t003-3" xlink:href="pone.0041339.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Transcript</td><td align="left" rowspan="1" colspan="1">Symbol</td><td align="left" rowspan="1" colspan="1">Definition</td><td align="left" rowspan="1" colspan="1">Fold change</td><td align="left" rowspan="1" colspan="1">P-value</td></tr><tr><td colspan="5" align="left" rowspan="1">INFLAMMATION RELATED GENES</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Cytokines and cytokine receptors</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NM_000628.3</td><td align="left" rowspan="1" colspan="1">IL10RB</td><td align="left" rowspan="1" colspan="1">Interleukin 10 receptor</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_005535.1</td><td align="left" rowspan="1" colspan="1">IL12RB1</td><td align="left" rowspan="1" colspan="1">Interleukin 12 receptor, &#x003b2;1</td><td align="left" rowspan="1" colspan="1">1.10</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_001560.2</td><td align="left" rowspan="1" colspan="1">IL13RA1</td><td align="left" rowspan="1" colspan="1">Interleukin 13 receptor, &#x003b1;1</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_014339.3</td><td align="left" rowspan="1" colspan="1">IL17R</td><td align="left" rowspan="1" colspan="1">Interleukin 17 receptor</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_004633.3</td><td align="left" rowspan="1" colspan="1">IL1R2</td><td align="left" rowspan="1" colspan="1">Interleukin 1 receptor, type II</td><td align="left" rowspan="1" colspan="1">0.83</td><td align="left" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_002182.2</td><td align="left" rowspan="1" colspan="1">IL1RAP</td><td align="left" rowspan="1" colspan="1">Interleukin 1 receptor accessory protein</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_173842.1</td><td align="left" rowspan="1" colspan="1">IL1RN</td><td align="left" rowspan="1" colspan="1">Interleukin 1 receptor antagonist</td><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">
<italic>0.052</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_181078.1</td><td align="left" rowspan="1" colspan="1">IL21R</td><td align="left" rowspan="1" colspan="1">Interleukin 21 receptor</td><td align="left" rowspan="1" colspan="1">1.10</td><td align="left" rowspan="1" colspan="1">
<italic>0.066</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_004843.2</td><td align="left" rowspan="1" colspan="1">IL27RA</td><td align="left" rowspan="1" colspan="1">Interleukin 27 receptor, &#x003b1;</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_000584.2</td><td align="left" rowspan="1" colspan="1">IL8</td><td align="left" rowspan="1" colspan="1">Interleukin 8</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_001557.2</td><td align="left" rowspan="1" colspan="1">IL8RB</td><td align="left" rowspan="1" colspan="1">Interleukin 8 receptor, &#x003b2;</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">
<italic>0.079</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Chemokines and chemokine receptors</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NM_002982.3</td><td align="left" rowspan="1" colspan="1">CCL2</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 2</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_002983.1</td><td align="left" rowspan="1" colspan="1">CCL3</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 3</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_001001437.3</td><td align="left" rowspan="1" colspan="1">CCL3L3</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 3-like 3</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_001337.3</td><td align="left" rowspan="1" colspan="1">CX3CR1</td><td align="left" rowspan="1" colspan="1">Chemokine (C-X3-C motif) receptor 1</td><td align="left" rowspan="1" colspan="1">1.49</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Inflammatory response</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NM_003264.3</td><td align="left" rowspan="1" colspan="1">TLR2</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 2</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_006068.2</td><td align="left" rowspan="1" colspan="1">TLR6</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 6</td><td align="left" rowspan="1" colspan="1">1.09</td><td align="left" rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_016562.3</td><td align="left" rowspan="1" colspan="1">TLR7</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 7</td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Interferon transcriptional regulation</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NM_002200.3</td><td align="left" rowspan="1" colspan="1">IRF5</td><td align="left" rowspan="1" colspan="1">Interferon regulatory factor 5</td><td align="left" rowspan="1" colspan="1">1.44</td><td align="left" rowspan="1" colspan="1">
<italic>0.051</italic>
</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="5" align="left" rowspan="1">OXIDATIVE STRESS RELATED GENES</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Antioxidants</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NM_002084.2</td><td align="left" rowspan="1" colspan="1">GPX3</td><td align="left" rowspan="1" colspan="1">Glutathione peroxidase 3</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_006793.2</td><td align="left" rowspan="1" colspan="1">PRDX3</td><td align="left" rowspan="1" colspan="1">Peroxiredoxin 3</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">
<italic>0.061</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_203472.1</td><td align="left" rowspan="1" colspan="1">SELS</td><td align="left" rowspan="1" colspan="1">Selenoprotein S</td><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">
<italic>0.060</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_005771.3</td><td align="left" rowspan="1" colspan="1">DHRS9</td><td align="left" rowspan="1" colspan="1">Dehydrogenase/reductase (SDR family) member 9</td><td align="left" rowspan="1" colspan="1">1.33</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>Genes involved in ROS metabolism</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NM_024505.2</td><td align="left" rowspan="1" colspan="1">NOX5</td><td align="left" rowspan="1" colspan="1">NADPH oxidase, EF-hand calcium binding domain 5</td><td align="left" rowspan="1" colspan="1">1.05</td><td align="left" rowspan="1" colspan="1">
<italic>0.052</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_001141.1</td><td align="left" rowspan="1" colspan="1">ALOX15B</td><td align="left" rowspan="1" colspan="1">Arachidonate 15-lipoxygenase, second type</td><td align="left" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="1" colspan="1">
<italic>0.084</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_004417.2</td><td align="left" rowspan="1" colspan="1">DUSP1</td><td align="left" rowspan="1" colspan="1">Dual specificity phosphatase 1</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">0.003</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s3c3"><title>Subanalysis with respect to CRP</title><p>After dividing the 18 patients in three groups, we compared the 6 patients with the lowest CRP levels with the patients with highest CRP levels; the middle tertile was left out of the comparison. This subanalysis confirmed that CRP does influence monocyte transcriptomes (<xref ref-type="table" rid="pone-0041339-t004">table 4</xref>). The group sizes become too small for a detailed comparison.</p><table-wrap id="pone-0041339-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0041339.t004</object-id><label>Table 4</label><caption><title>Number of differentially expressed genes at different expression and significance levels in patients with low CRP and high CRP compared to healthy controls at baseline.</title></caption><alternatives><graphic id="pone-0041339-t004-4" xlink:href="pone.0041339.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Middle</td><td align="left" rowspan="1" colspan="1">High</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N&#x0200a;=&#x0200a;</td><td align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (average, min-max)</td><td align="left" rowspan="1" colspan="1">
<bold>1.2 (1&#x02013;3)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.2 (3&#x02013;6)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>21.7 (7&#x02013;53)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Differentially expressed genes vs. controls</td><td align="left" rowspan="1" colspan="1">
<bold># of genes</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold># of genes</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">
<bold>717</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>771</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">
<bold>125</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>192</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>25</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>10</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x0003c;0.05 &#x00026; FC&#x0003c;0.74 or &#x0003e;1.35</td><td align="left" rowspan="1" colspan="1">
<bold>16</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>58</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x0003c;0.001 &#x00026; FC&#x0003c;0.82 or &#x0003e;1.2</td><td align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>21</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x0003c;0.0001 &#x00026; FC&#x0003c;0.91 or &#x0003e;1.1</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>10</bold>
</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s3c4"><title>Subanalysis with respect to individual variation in gene expression of the cardiorenal patients at baseline</title><p>Because of the relatively limited differential expression at baseline, we analyzed the homogeneity of the baseline samples of the CRS patients compared to the controls by comparing the standard deviation of the log<sub>2</sub> ratios. Indeed, 4 out of the 18 patients showed substantial variation in log<sub>2</sub> ratios whereas the other did show minimal variation. The number was too small to investigate whether the response to EPO of these 4 patients was different from the 14 other patients.</p></sec></sec><sec id="s3d"><title>Monocyte gene expression in cardiorenal syndrome patients after 18 days of currently recommended dose erythropoietin treatment</title><sec id="s3d1"><title>Global gene expression profile changes, hierarchical clustering</title><p>The effect of 18 days EPO treatment was assessed in the 12 CRS patients before and after the initiation of EPO treatment. Out of 25,528 genes explored, signals of 12,198 genes exceeded background in the monocyte transcriptome before and/or after treatment. Of these, 399 genes were significantly differentially modulated by EPO (p-value&#x0003c;0.05; 1.5% of total assessed genes; see table S3). Fold changes were low in this comparison (range 0.58&#x02013;3.49); differential modulation of 211 genes was &#x0003e;1.10 or &#x0003c;0.90 fold. Strikingly, Euclidean clustering with these genes demonstrated that treated patient clustered close to his/her own baseline gene profile (<xref ref-type="fig" rid="pone-0041339-g002">figure 2</xref> and <xref ref-type="supplementary-material" rid="pone.0041339.s001">figure S1</xref>). Although our intervention study was not designed to that purpose. clustering of patients did not seem to be associated with age, gender, or the presence of diabetes.</p><fig id="pone-0041339-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0041339.g002</object-id><label>Figure 2</label><caption><title>Euclidean cluster analysis for patients before and after erythropoietin treatment.</title><p>Patient number and time point of sample collection (patient 1, timepoint 1&#x0200a;=&#x0200a;11; patient 1, timepoint 2&#x0200a;=&#x0200a;12, etc) are listed in order of monocyte transcriptomes similarity. The closer samples are depicted to each other, the more comparable transcriptomes are. Only the first 50 genes are depicted, the full figure is online.</p></caption><graphic xlink:href="pone.0041339.g002"/></fig></sec><sec id="s3d2"><title>Specific gene expression changes</title><p>The 3 EPO injections only increased HBB and HBA2 expressions significantly with a fold change&#x0003e;1.35 when comparing group mean gene intensities. As mentioned, expression of these two genes may be attributed to reticulocyte contamination. Subsequently, to evaluate if short-term EPO treatment demonstrated monocyte gene modulations with regard to inflammation or oxidative stress we assessed gene expression changes in selected gene panels. None of the genes were differentially expressed with a p-value&#x0003c;0.05 (table S4).</p></sec><sec id="s3d3"><title>Individual gene response to erythropoietin</title><p>Since the expression profile of the treated group did not substantially differ from baseline, we compared gene expression modulations in the twelve individual patients. The individual gene response to EPO was remarkably variable in all patients. Only two genes (HBB, HBA2) were induced and one gene downregulated (RAMP2) in more than two patients after treatment.</p></sec></sec></sec><sec id="s4"><title>Discussion</title><p>The present study is based on three of our recent studies in humans. The first showed altered leukocyte gene expression in untreated hypertensive patients, which was strongly attenuated in matched, well-treated patients <xref rid="pone.0041339-Chon1" ref-type="bibr">[16]</xref>. In the other two papers, monocytes gene expressions in CKD <xref rid="pone.0041339-Rastmanesh1" ref-type="bibr">[20]</xref> and end-stage renal disease <xref rid="pone.0041339-Rastmanesh2" ref-type="bibr">[21]</xref> patients showed induction of the so-called suppressors of cytokine signaling, which modulate the Jak/Stat transcription pathway and steer the actions of IFN&#x003b3; and IL6 <xref rid="pone.0041339-Lang1" ref-type="bibr">[32]</xref>. Therefore, we hypothesized that monocytes, as cells involved in atherosclerosis <xref rid="pone.0041339-Ardigo1" ref-type="bibr">[15]</xref>, <xref rid="pone.0041339-Chon2" ref-type="bibr">[33]</xref>, could function as biosensors of the systemic environment of CRS patients with anemia and of the effects of short-term EPO treatment.</p><p>When comparing monocyte transcriptomes in CRS patients to healthy controls, one of the most remarkable observations is the limited number of changes, which could have a number of potential explanations. First, the study subjects were carefully selected, stable cardiorenal failure patients; the regular treatment, including angiotensin blockade (89%), statins (56%), acetylsalicylic acid (44%) and &#x003b2;-blockers (72%) may have dampened gene expression changes, even though the inflammatory environment was not completely normalized as judged from increased hsCRP levels. In this regard, monocytes displayed slightly higher numbers of genes with modulated expression in subjects with higher CRP values, than in subjects with lower CRP values. Unfortunately, the sample size is too small and the percentage of patients on medication too high to separate out the influence of any of the individual drugs. Second, it may be that the monocyte has adapted to the continuous exposure of stimuli, e.g. inflammation and oxidative stress. However, if this were the case, we would expect to see more &#x02018;imprints&#x02019; of such adaptations in the transcriptome (e.g. more pronounced induction of anti-oxidant genes). Third, critical changes in monocytes of cardiorenal patients may be not achieved at the level of gene transcription but at the level of protein synthesis, modification and trafficking. It is unlikely that the choice of Illumina arrays underlies the paucity of changes, since this platform provided highly reproducible results and revealed important biological processes in monocytes <xref rid="pone.0041339-Maouche1" ref-type="bibr">[34]</xref>. In our own laboratory, the same platform yielded very strong transcriptional responses of endothelial cells in culture to IFN&#x003b3; and IL6 <xref rid="pone.0041339-Bluyssen1" ref-type="bibr">[35]</xref>. Regarding the methodology applied in the present study, we did not correct for multiple testing using methods such as FDR, because of the small sample size. Therefore, the possibility exists that some of the reported changes in expression could be false positives. In another EPOCARES sub-study, which evaluated the responses of plasma hepcidin to the same short-term low dose EPO stimulation <xref rid="pone.0041339-vanderPutten2" ref-type="bibr">[24]</xref>, we found clear responses in plasma hepcidin levels and reticulocyte numbers, clearly indicating that the dose of EPO was sufficiently strong to appreciably affect iron metabolism and erythropoiesis <xref rid="pone.0041339-vanderPutten1" ref-type="bibr">[23]</xref>. A last explanation is that the group is quite heterogeneous, as exemplified by the analysis of variation in log<sub>2</sub> values of each patient.</p><p>The pathophysiology of CRS is complex and likely involves disruption of the pro-/anti-inflammatory and pro-/anti-oxidant balance, and enhanced activity of the SNS. We investigated whether monocytes reveal imprints of such alterations. Earlier studies in our group reported modulated expression of SOCS genes in monocytes of CKD patients <xref rid="pone.0041339-Rastmanesh1" ref-type="bibr">[20]</xref>. We found increased CX3CR1 expression in CRS patients. CX3CR1 binds fractalkine (CX3CL1), a CX3C chemokine, which is expressed by activated endothelial cells and mediates adhesion and chemotaxis of CX3CR1 expressing monocytes and accumulation of macrophages in atherosclerotic lesions <xref rid="pone.0041339-Combadiere1" ref-type="bibr">[36]</xref>. Transcription of some genes that stimulate inflammation (e.g. IL8, IL1RAP) was decreased in CRS patients compared to healthy controls, which may indicate negative feedback in response to inflammation. All-in-all, our analysis does not point to the cytokines IL6, IFN&#x003b3; and TNF&#x003b1;, that have classically been associated with low grade inflammation in cardiovascular disease <xref rid="pone.0041339-Lind1" ref-type="bibr">[37]</xref> and renal failure <xref rid="pone.0041339-Malaponte1" ref-type="bibr">[38]</xref>. Nevertheless, the transcriptome seemed to be responsive to the level of inflammation, since higher CRP levels were associated with more changes in monocyte gene expression.</p><p>Considering the pro/anti-oxidant balance in CRS patients, expression changes were modest. Downregulation of genes encoding for proteins with anti-oxidative action is suggested (e.g. GPX3, PRDX3), though others were induced (DHRS9). Decreased expression of oxidative stress responsive gene DUSP1 and markers of early activation FOS and EGR1 possibly reflects downregulation of gene expression in activated cells from our patients. This phenomenon has been reported previously in patients with coronary artery disease <xref rid="pone.0041339-Schirmer1" ref-type="bibr">[39]</xref>.</p><p>The only change in CRS patients related to the SNS was increased expression of ADRB2, the adrenergic receptor &#x003b2;2 subtype that binds epinephrine and norepinephrine <xref rid="pone.0041339-Strader1" ref-type="bibr">[40]</xref>. This gene is involved in coupling the SNS to immune cell function <xref rid="pone.0041339-Elenkov1" ref-type="bibr">[41]</xref>. Sympathetic hyperactivity is present in patients with heart <xref rid="pone.0041339-Jackson1" ref-type="bibr">[42]</xref> and failure <xref rid="pone.0041339-Koomans1" ref-type="bibr">[43]</xref>. It was expected that chronic sympathetic hyperactivity would lead to downregulation of adrenoceptor density <xref rid="pone.0041339-Fraser1" ref-type="bibr">[44]</xref>, which underlies the decrease in &#x003b2;-adrenoreceptor-mediated responsiveness characteristic <xref rid="pone.0041339-Bristow1" ref-type="bibr">[45]</xref>, <xref rid="pone.0041339-Brodde1" ref-type="bibr">[46]</xref>. However, &#x003b2;-blockade was previously shown to increase adrenoreceptor density in leukocytes. Patients with the highest catecholamine levels had the greatest rise in receptor density following &#x003b2;-blockade <xref rid="pone.0041339-Fraser1" ref-type="bibr">[44]</xref>. Albeit speculative, since 72% of our patients received &#x003b2;-blockade, higher ADRB2 expression levels may indicate higher baseline sympathetic activity compared to our healthy controls.</p><p>Our second aim was to evaluate short-term treatment with a currently recommended EPO dose for renal anemia in this patient population. In another arm of this study, there was a clear decrease in hepcidin, an increase in reticulocytes, an increase in serum transferrin receptor and in iron saturation <xref rid="pone.0041339-vanderPutten2" ref-type="bibr">[24]</xref> after 2 weeks of EPO. At 26 weeks, all of the patients except for 2 had a clear increase in haemoglobin levels <xref rid="pone.0041339-Jie2" ref-type="bibr">[47]</xref>, and/or had been subjected to phlebotomy (this is in the group in which in the longer run, Hgb levels were kept stable by phlebotomy). We postulated previously that EPO may dampen activated inflammatory and oxidative stress systems in CRS patients <xref rid="pone.0041339-Jie1" ref-type="bibr">[5]</xref>. By evaluating transcriptomes after 18 days of EPO therapy, direct effects of EPO should be discriminated from hematopoietic effects. However, EPO treatment did not substantially modulate the monocyte transcriptome in our study. The transcriptome after short-term EPO therapy closely clustered with to the baseline expression profile for every patient in our cluster analysis. This suggests that individual differences overrule the direct, short-term effects of EPO. Furthermore, we found a highly variable gene expression response to EPO in all patients, which hampers the detection of group differences. The finding that EPO response at gene expression level is so diverse may point at the variable clinical response to EPO.</p><p>Several reasons may underlie the unexpected lack in differential gene expression in response to EPO treatment. First, it was remarkable that individual responses to EPO were so variable, which hinders detection of global gene expression changes between groups. Despite careful selection of patients and optimally standardizing medical treatment, individual variations still seem to dominate the effect of EPO therapy. Microarray technology has shown to reflect the clinical response to medical therapy <xref rid="pone.0041339-Chon1" ref-type="bibr">[16]</xref>, <xref rid="pone.0041339-WibautBerlaimont1" ref-type="bibr">[17]</xref>. Our study certainly does not rule out that transcriptome analysis on circulating cells could be applied to monitor early responses to EPO, however, another cell type may better reflect the changes induces by EPO <xref rid="pone.0041339-Ardigo1" ref-type="bibr">[15]</xref>. One could think of endothelial progenitor cells, that might better reflect the response of a target tissue to EPO, or reticulocytes, that might better reflect the response of the bone marrow to EPO. Studying targets organ cells per se obviously is more invasive. Second, the dose and duration of EPO treatment must be considered. Various animal studies have shown protective effects of EPO in acute ischemia/reperfusion injury of the heart and kidney <xref rid="pone.0041339-Chang1" ref-type="bibr">[13]</xref>, <xref rid="pone.0041339-Parsa1" ref-type="bibr">[14]</xref>. EPO doses used in these studies are considerably higher, ranging from 3000&#x02013;5000 U/kg, which is much higher than the dosages usually applied in CKD and end-stage renal disease patients. However, recent evidence from the CHOIR study shows that chronic administration of high EPO dose (mean dose 11215 IU/wk) is associated with adverse clinical events. Since we treat our patients up to 1 year, we chose a currently recommended dose for the treatment of renal anemia of 50 IU/kg/wk (i.e. approximately 3000 IU/wk), and not a short-term high dose treatment. As alternative to the present design, that aimed to study both short and long term effects of EPO which did not justify using a higher dose, one could possibly safely study the effect of one single dose of a higher concentration of EPO in humans. Altogether, the present data do not support a beneficial role for non-hematopoietic, short-term effects of low dose EPO. More importantly, using monocyte transcriptomes, we were unable to demonstrate any harmful effects.</p><p>In summary, we demonstrate that differences in the gene expression of monocytes, being biosensors of the pro-atherogenic environment and mediators of early atherosclerosis, are limited in our study subjects. Nevertheless, the observed changes point at two of the systems we have proposed as important connectors in combined heart and renal failure, being inflammation and oxidative stress. We also demonstrate that in monocytes, response in gene expression to short-term administration of the currently recommended dose of EPO is very limited, indicating that a dose that is commonly used to combat the EPO deficiency of renal anemia does not exert important non-hematopoietic effects on this pivotal cell. Fortunately, we also have been unable to identify any undesirable effects of this widely applied dose of EPO. Further studies are necessary to investigate whether other immune cells involved in the inflammatory response and in atherosclerosis may be more sensitive to this recommended dose of EPO and whether higher doses of EPO as used in cardiovascular trials do affect monocyte gene expression.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0041339.s001"><label>Figure S1</label><caption><p>Euclidean cluster analysis for patients before and after erythropoietin treatment. Patient number and time point of sample collection (patient 1, timepoint 1&#x0200a;=&#x0200a;11; patient 1, timepoint 2&#x0200a;=&#x0200a;12, etc) are listed in order of monocyte transcriptomes similarity. The closer samples are depicted to each other, the more comparable transcriptomes are.</p><p>(TIF)</p></caption><media xlink:href="pone.0041339.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0041339.s002"><label>Table S1</label><caption><p>Monocyte gene expression differences in CRS patients at baseline (n&#x0200a;=&#x0200a;18) compared to healthy controls (n&#x0200a;=&#x0200a;12).</p><p>(PDF)</p></caption><media xlink:href="pone.0041339.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0041339.s003"><label>Table S2</label><caption><p>Cardiorenal connector monocyte gene expression panel: differences in CRS patients at baseline (n&#x0200a;=&#x0200a;18) compared to healthy controls (n&#x0200a;=&#x0200a;12).</p><p>(PDF)</p></caption><media xlink:href="pone.0041339.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0041339.s004"><label>Table S3</label><caption><p>Monocyte gene expression changes in CRS patients (n&#x0200a;=&#x0200a;12) after 2 weeks of EPO treatment.</p><p>(PDF)</p></caption><media xlink:href="pone.0041339.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0041339.s005"><label>Table S4</label><caption><p>Cardiorenal connector monocyte gene expression panel: changes in CRS patients (n&#x0200a;=&#x0200a;12) after 2 weeks of EPO treatment.</p><p>(PDF)</p></caption><media xlink:href="pone.0041339.s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to thank Adry Diepenbroek and Mireille Emans from the Meander MC Amersfoort for their excellent patient care assistance.</p></ack><ref-list><title>References</title><ref id="pone.0041339-Hillege1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Hillege</surname><given-names>HL</given-names></name>, <name><surname>Nitsch</surname><given-names>D</given-names></name>, <name><surname>Pfeffer</surname><given-names>MA</given-names></name>, <name><surname>Swedberg</surname><given-names>K</given-names></name>, <name><surname>McMurray</surname><given-names>JJ</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Renal function as a predictor of outcome in a broad spectrum of patients with heart failure</article-title>. <source>Circulation</source>
<volume>113</volume>: <fpage>671</fpage>&#x02013;<lpage>678</lpage>.<pub-id pub-id-type="pmid">16461840</pub-id></mixed-citation></ref><ref id="pone.0041339-Foley1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Foley</surname><given-names>RN</given-names></name>, <name><surname>Parfrey</surname><given-names>PS</given-names></name>, <name><surname>Sarnak</surname><given-names>MJ</given-names></name> (<year>1998</year>) <article-title>Clinical epidemiology of cardiovascular disease in chronic renal disease</article-title>. <source>Am J Kidney Dis</source>
<volume>32</volume>: <fpage>S112</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">9820470</pub-id></mixed-citation></ref><ref id="pone.0041339-Bongartz1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Bongartz</surname><given-names>LG</given-names></name>, <name><surname>Cramer</surname><given-names>MJ</given-names></name>, <name><surname>Doevendans</surname><given-names>PA</given-names></name>, <name><surname>Joles</surname><given-names>JA</given-names></name>, <name><surname>Braam</surname><given-names>B</given-names></name> (<year>2005</year>) <article-title>The severe cardiorenal syndrome: &#x02018;Guyton revisited&#x02019;</article-title>. <source>Eur Heart J</source>
<volume>26</volume>: <fpage>11</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">15615794</pub-id></mixed-citation></ref><ref id="pone.0041339-Coulon1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Coulon</surname><given-names>S</given-names></name>, <name><surname>Dussiot</surname><given-names>M</given-names></name>, <name><surname>Grapton</surname><given-names>D</given-names></name>, <name><surname>Maciel</surname><given-names>TT</given-names></name>, <name><surname>Wang</surname><given-names>PH</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia</article-title>. <source>Nature medicine</source>
<volume>17</volume>: <fpage>1456</fpage>&#x02013;<lpage>1465</lpage>.</mixed-citation></ref><ref id="pone.0041339-Jie1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Jie</surname><given-names>KE</given-names></name>, <name><surname>Verhaar</surname><given-names>MC</given-names></name>, <name><surname>Cramer</surname><given-names>MJ</given-names></name>, <name><surname>van der Putten</surname><given-names>K</given-names></name>, <name><surname>Gaillard</surname><given-names>CA</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors</article-title>. <source>Am J Physiol Renal Physiol</source>
<volume>291</volume>: <fpage>F932</fpage>&#x02013;<lpage>944</lpage>.<pub-id pub-id-type="pmid">16885153</pub-id></mixed-citation></ref><ref id="pone.0041339-Lisowska1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Lisowska</surname><given-names>KA</given-names></name>, <name><surname>Debska-Slizien</surname><given-names>A</given-names></name>, <name><surname>Bryl</surname><given-names>E</given-names></name>, <name><surname>Rutkowski</surname><given-names>B</given-names></name>, <name><surname>Witkowski</surname><given-names>JM</given-names></name> (<year>2010</year>) <article-title>Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment</article-title>. <source>Artificial organs</source>
<volume>34</volume>: <fpage>654</fpage>&#x02013;<lpage>662</lpage>.<pub-id pub-id-type="pmid">20528849</pub-id></mixed-citation></ref><ref id="pone.0041339-Groenveld1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Groenveld</surname><given-names>HF</given-names></name>, <name><surname>Januzzi</surname><given-names>JL</given-names></name>, <name><surname>Damman</surname><given-names>K</given-names></name>, <name><surname>van Wijngaarden</surname><given-names>J</given-names></name>, <name><surname>Hillege</surname><given-names>HL</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Anemia and mortality in heart failure patients a systematic review and meta-analysis</article-title>. <source>J Am Coll Cardiol</source>
<volume>52</volume>: <fpage>818</fpage>&#x02013;<lpage>827</lpage>.<pub-id pub-id-type="pmid">18755344</pub-id></mixed-citation></ref><ref id="pone.0041339-Sarnak1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Sarnak</surname><given-names>MJ</given-names></name>, <name><surname>Tighiouart</surname><given-names>H</given-names></name>, <name><surname>Manjunath</surname><given-names>G</given-names></name>, <name><surname>MacLeod</surname><given-names>B</given-names></name>, <name><surname>Griffith</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study</article-title>. <source>J Am Coll Cardiol</source>
<volume>40</volume>: <fpage>27</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">12103252</pub-id></mixed-citation></ref><ref id="pone.0041339-Drueke1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Drueke</surname><given-names>TB</given-names></name>, <name><surname>Locatelli</surname><given-names>F</given-names></name>, <name><surname>Clyne</surname><given-names>N</given-names></name>, <name><surname>Eckardt</surname><given-names>KU</given-names></name>, <name><surname>Macdougall</surname><given-names>IC</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Normalization of hemoglobin level in patients with chronic kidney disease and anemia</article-title>. <source>N Engl J Med</source>
<volume>355</volume>: <fpage>2071</fpage>&#x02013;<lpage>2084</lpage>.<pub-id pub-id-type="pmid">17108342</pub-id></mixed-citation></ref><ref id="pone.0041339-Pfeffer1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Pfeffer</surname><given-names>MA</given-names></name>, <name><surname>Burdmann</surname><given-names>EA</given-names></name>, <name><surname>Chen</surname><given-names>YJ</given-names></name>, <name><surname>Cooper</surname><given-names>ME</given-names></name>, <name><surname>De Zeeuw</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>A trial of darbepoietin alpha in type 2 diabetes and chronic kidney disease</article-title>. <source>N Engl J Med</source>
<volume>361</volume>: <fpage>2019</fpage>&#x02013;<lpage>2032</lpage>.<pub-id pub-id-type="pmid">19880844</pub-id></mixed-citation></ref><ref id="pone.0041339-Singh1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Singh</surname><given-names>AK</given-names></name>, <name><surname>Szczech</surname><given-names>L</given-names></name>, <name><surname>Tang</surname><given-names>KL</given-names></name>, <name><surname>Barnhart</surname><given-names>H</given-names></name>, <name><surname>Sapp</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Correction of anemia with epoetin alfa in chronic kidney disease</article-title>. <source>N Engl J Med</source>
<volume>355</volume>: <fpage>2085</fpage>&#x02013;<lpage>2098</lpage>.<pub-id pub-id-type="pmid">17108343</pub-id></mixed-citation></ref><ref id="pone.0041339-Szczech1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Szczech</surname><given-names>LA</given-names></name>, <name><surname>Barnhart</surname><given-names>HX</given-names></name>, <name><surname>Inrig</surname><given-names>JK</given-names></name>, <name><surname>Reddan</surname><given-names>DN</given-names></name>, <name><surname>Sapp</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes</article-title>. <source>Kidney Int</source>
<volume>74</volume>: <fpage>791</fpage>&#x02013;<lpage>798</lpage>.<pub-id pub-id-type="pmid">18596733</pub-id></mixed-citation></ref><ref id="pone.0041339-Chang1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>YK</given-names></name>, <name><surname>Choi</surname><given-names>DE</given-names></name>, <name><surname>Na</surname><given-names>KR</given-names></name>, <name><surname>Lee</surname><given-names>SJ</given-names></name>, <name><surname>Suh</surname><given-names>KS</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects</article-title>. <source>J Urol</source>
<volume>181</volume>: <fpage>1434</fpage>&#x02013;<lpage>1443</lpage>.<pub-id pub-id-type="pmid">19157461</pub-id></mixed-citation></ref><ref id="pone.0041339-Parsa1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Parsa</surname><given-names>CJ</given-names></name>, <name><surname>Matsumoto</surname><given-names>A</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Riel</surname><given-names>RU</given-names></name>, <name><surname>Pascal</surname><given-names>LS</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>A novel protective effect of erythropoietin in the infarcted heart</article-title>. <source>J Clin Invest</source>
<volume>112</volume>: <fpage>999</fpage>&#x02013;<lpage>1007</lpage>.<pub-id pub-id-type="pmid">14523037</pub-id></mixed-citation></ref><ref id="pone.0041339-Ardigo1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Ardigo</surname><given-names>D</given-names></name>, <name><surname>Gaillard</surname><given-names>CA</given-names></name>, <name><surname>Braam</surname><given-names>B</given-names></name> (<year>2007</year>) <article-title>Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease</article-title>. <source>Clin Chem Lab Med</source>
<volume>45</volume>: <fpage>1109</fpage>&#x02013;<lpage>1120</lpage>.<pub-id pub-id-type="pmid">17635069</pub-id></mixed-citation></ref><ref id="pone.0041339-Chon1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Chon</surname><given-names>H</given-names></name>, <name><surname>Gaillard</surname><given-names>CA</given-names></name>, <name><surname>van der Meijden</surname><given-names>BB</given-names></name>, <name><surname>Dijstelbloem</surname><given-names>HM</given-names></name>, <name><surname>Kraaijenhagen</surname><given-names>RJ</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment</article-title>. <source>Hypertension</source>
<volume>43</volume>: <fpage>947</fpage>&#x02013;<lpage>951</lpage>.<pub-id pub-id-type="pmid">15007037</pub-id></mixed-citation></ref><ref id="pone.0041339-WibautBerlaimont1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Wibaut-Berlaimont</surname><given-names>V</given-names></name>, <name><surname>Randi</surname><given-names>AM</given-names></name>, <name><surname>Mandryko</surname><given-names>V</given-names></name>, <name><surname>Lunnon</surname><given-names>MW</given-names></name>, <name><surname>Haskard</surname><given-names>DO</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis</article-title>. <source>J Thromb Haemost</source>
<volume>3</volume>: <fpage>677</fpage>&#x02013;<lpage>685</lpage>.<pub-id pub-id-type="pmid">15842352</pub-id></mixed-citation></ref><ref id="pone.0041339-AbdAlla1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>AbdAlla</surname><given-names>S</given-names></name>, <name><surname>Lother</surname><given-names>H</given-names></name>, <name><surname>Langer</surname><given-names>A</given-names></name>, <name><surname>el Faramawy</surname><given-names>Y</given-names></name>, <name><surname>Quitterer</surname><given-names>U</given-names></name> (<year>2004</year>) <article-title>Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis</article-title>. <source>Cell</source>
<volume>119</volume>: <fpage>343</fpage>&#x02013;<lpage>354</lpage>.<pub-id pub-id-type="pmid">15507206</pub-id></mixed-citation></ref><ref id="pone.0041339-Sprague1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Sprague</surname><given-names>AH</given-names></name>, <name><surname>Khalil</surname><given-names>RA</given-names></name> (<year>2009</year>) <article-title>Inflammatory cytokines in vascular dysfunction and vascular disease</article-title>. <source>Biochem Pharmacol</source>
</mixed-citation></ref><ref id="pone.0041339-Rastmanesh1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Rastmanesh</surname><given-names>MM</given-names></name>, <name><surname>Bluyssen</surname><given-names>HA</given-names></name>, <name><surname>Joles</surname><given-names>JA</given-names></name>, <name><surname>Boer</surname><given-names>P</given-names></name>, <name><surname>Willekes</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease</article-title>. <source>Eur J Pharmacol</source>
<volume>593</volume>: <fpage>99</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">18656467</pub-id></mixed-citation></ref><ref id="pone.0041339-Rastmanesh2"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Rastmanesh</surname><given-names>MM</given-names></name>, <name><surname>Braam</surname><given-names>B</given-names></name>, <name><surname>Joles</surname><given-names>JA</given-names></name>, <name><surname>Boer</surname><given-names>P</given-names></name>, <name><surname>Bluyssen</surname><given-names>HA</given-names></name> (<year>2009</year>) <article-title>Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality</article-title>. <source>Eur J Pharmacol</source>
<volume>602</volume>: <fpage>163</fpage>&#x02013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">19041303</pub-id></mixed-citation></ref><ref id="pone.0041339-Meier1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Meier</surname><given-names>P</given-names></name>, <name><surname>Antonov</surname><given-names>J</given-names></name>, <name><surname>Zbinden</surname><given-names>R</given-names></name>, <name><surname>Kuhn</surname><given-names>A</given-names></name>, <name><surname>Zbinden</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Non-invasive gene-expression-based detection of well-developed collateral function in individuals with and without coronary artery disease</article-title>. <source>Heart</source>
<volume>95</volume>: <fpage>900</fpage>&#x02013;<lpage>908</lpage>.<pub-id pub-id-type="pmid">18728069</pub-id></mixed-citation></ref><ref id="pone.0041339-vanderPutten1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>van der Putten</surname><given-names>K</given-names></name>, <name><surname>Jie</surname><given-names>KE</given-names></name>, <name><surname>Emans</surname><given-names>ME</given-names></name>, <name><surname>Verhaar</surname><given-names>MC</given-names></name>, <name><surname>Joles</surname><given-names>JA</given-names></name>, <etal>et al</etal> (<year>Prelim citation</year>) <article-title>Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study</article-title>. <source>J Nephrol</source>
<volume>23</volume>: <fpage>363</fpage>&#x02013;<lpage>368</lpage>.<pub-id pub-id-type="pmid">20383871</pub-id></mixed-citation></ref><ref id="pone.0041339-vanderPutten2"><label>24</label><mixed-citation publication-type="journal">
<name><surname>van der Putten</surname><given-names>K</given-names></name>, <name><surname>Jie</surname><given-names>KE</given-names></name>, <name><surname>van den Broek</surname><given-names>D</given-names></name>, <name><surname>Kraaijenhagen</surname><given-names>RJ</given-names></name>, <name><surname>Laarakkers</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients</article-title>. <source>Eur J Heart Fail</source>
<volume>12</volume>: <fpage>943</fpage>&#x02013;<lpage>950</lpage>.<pub-id pub-id-type="pmid">20601671</pub-id></mixed-citation></ref><ref id="pone.0041339-Dickstein1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Dickstein</surname><given-names>K</given-names></name>, <name><surname>Cohen-Solal</surname><given-names>A</given-names></name>, <name><surname>Filippatos</surname><given-names>G</given-names></name>, <name><surname>McMurray</surname><given-names>JJ</given-names></name>, <name><surname>Ponikowski</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)</article-title>. <source>Eur Heart J</source>
<volume>29</volume>: <fpage>2388</fpage>&#x02013;<lpage>2442</lpage>.<pub-id pub-id-type="pmid">18799522</pub-id></mixed-citation></ref><ref id="pone.0041339-Paulus1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Paulus</surname><given-names>WJ</given-names></name>, <name><surname>Tschope</surname><given-names>C</given-names></name>, <name><surname>Sanderson</surname><given-names>JE</given-names></name>, <name><surname>Rusconi</surname><given-names>C</given-names></name>, <name><surname>Flachskampf</surname><given-names>FA</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology</article-title>. <source>Eur Heart J</source>
<volume>28</volume>: <fpage>2539</fpage>&#x02013;<lpage>2550</lpage>.<pub-id pub-id-type="pmid">17428822</pub-id></mixed-citation></ref><ref id="pone.0041339-Pfeffer2"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Pfeffer</surname><given-names>MA</given-names></name>, <name><surname>Burdmann</surname><given-names>EA</given-names></name>, <name><surname>Chen</surname><given-names>CY</given-names></name>, <name><surname>Cooper</surname><given-names>ME</given-names></name>, <name><surname>de Zeeuw</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease</article-title>. <source>N Engl J Med</source>
<volume>361</volume>: <fpage>2019</fpage>&#x02013;<lpage>2032</lpage>.<pub-id pub-id-type="pmid">19880844</pub-id></mixed-citation></ref><ref id="pone.0041339-Blazejczyk1"><label>28</label><mixed-citation publication-type="other">Blazejczyk M, Miron M, Nadon R (2007) FlexArray: A statistical data analysis software for gene expression microarrays. Montreal, Quebec, Canada.: Genome Quebec, Canada.</mixed-citation></ref><ref id="pone.0041339-Baldi1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Baldi</surname><given-names>P</given-names></name>, <name><surname>Long</surname><given-names>AD</given-names></name> (<year>2001</year>) <article-title>A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes</article-title>. <source>Bioinformatics</source>
<volume>17</volume>: <fpage>509</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">11395427</pub-id></mixed-citation></ref><ref id="pone.0041339-Saeed1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Saeed</surname><given-names>AI</given-names></name>, <name><surname>Bhagabati</surname><given-names>NK</given-names></name>, <name><surname>Braisted</surname><given-names>JC</given-names></name>, <name><surname>Liang</surname><given-names>W</given-names></name>, <name><surname>Sharov</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>TM4 microarray software suite</article-title>. <source>Methods in enzymology</source>
<volume>411</volume>: <fpage>134</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">16939790</pub-id></mixed-citation></ref><ref id="pone.0041339-Edgar1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Edgar</surname><given-names>R</given-names></name>, <name><surname>Domrachev</surname><given-names>M</given-names></name>, <name><surname>Lash</surname><given-names>AE</given-names></name> (<year>2002</year>) <article-title>Gene Expression Omnibus: NCBI gene expression and hybridization array data repository</article-title>. <source>Nucleic Acids Res</source>
<volume>30</volume>: <fpage>207</fpage>&#x02013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">11752295</pub-id></mixed-citation></ref><ref id="pone.0041339-Lang1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Lang</surname><given-names>R</given-names></name>, <name><surname>Pauleau</surname><given-names>AL</given-names></name>, <name><surname>Parganas</surname><given-names>E</given-names></name>, <name><surname>Takahashi</surname><given-names>Y</given-names></name>, <name><surname>Mages</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>SOCS3 regulates the plasticity of gp130 signaling</article-title>. <source>Nat Immunol</source>
<volume>4</volume>: <fpage>546</fpage>&#x02013;<lpage>550</lpage>.<pub-id pub-id-type="pmid">12754506</pub-id></mixed-citation></ref><ref id="pone.0041339-Chon2"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Chon</surname><given-names>H</given-names></name>, <name><surname>Verhaar</surname><given-names>MC</given-names></name>, <name><surname>Koomans</surname><given-names>HA</given-names></name>, <name><surname>Joles</surname><given-names>JA</given-names></name>, <name><surname>Braam</surname><given-names>B</given-names></name> (<year>2006</year>) <article-title>Role of circulating karyocytes in the initiation and progression of atherosclerosis</article-title>. <source>Hypertension</source>
<volume>47</volume>: <fpage>803</fpage>&#x02013;<lpage>810</lpage>.<pub-id pub-id-type="pmid">16520401</pub-id></mixed-citation></ref><ref id="pone.0041339-Maouche1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Maouche</surname><given-names>S</given-names></name>, <name><surname>Poirier</surname><given-names>O</given-names></name>, <name><surname>Godefroy</surname><given-names>T</given-names></name>, <name><surname>Olaso</surname><given-names>R</given-names></name>, <name><surname>Gut</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells</article-title>. <source>BMC Genomics</source>
<volume>9</volume>: <fpage>302</fpage>.<pub-id pub-id-type="pmid">18578872</pub-id></mixed-citation></ref><ref id="pone.0041339-Bluyssen1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Bluyssen</surname><given-names>HA</given-names></name>, <name><surname>Rastmanesh</surname><given-names>MM</given-names></name>, <name><surname>Tilburgs</surname><given-names>C</given-names></name>, <name><surname>Jie</surname><given-names>K</given-names></name>, <name><surname>Wesseling</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells</article-title>. <source>Am J Physiol Cell Physiol</source>
<volume>299</volume>: <fpage>C354</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">20484656</pub-id></mixed-citation></ref><ref id="pone.0041339-Combadiere1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Combadiere</surname><given-names>C</given-names></name>, <name><surname>Potteaux</surname><given-names>S</given-names></name>, <name><surname>Gao</surname><given-names>JL</given-names></name>, <name><surname>Esposito</surname><given-names>B</given-names></name>, <name><surname>Casanova</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice</article-title>. <source>Circulation</source>
<volume>107</volume>: <fpage>1009</fpage>&#x02013;<lpage>1016</lpage>.<pub-id pub-id-type="pmid">12600915</pub-id></mixed-citation></ref><ref id="pone.0041339-Lind1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Lind</surname><given-names>L</given-names></name> (<year>2003</year>) <article-title>Circulating markers of inflammation and atherosclerosis</article-title>. <source>Atherosclerosis</source>
<volume>169</volume>: <fpage>203</fpage>&#x02013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">12921971</pub-id></mixed-citation></ref><ref id="pone.0041339-Malaponte1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Malaponte</surname><given-names>G</given-names></name>, <name><surname>Bevelacqua</surname><given-names>V</given-names></name>, <name><surname>Fatuzzo</surname><given-names>P</given-names></name>, <name><surname>Rapisarda</surname><given-names>F</given-names></name>, <name><surname>Emmanuele</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age</article-title>. <source>Nephrol Dial Transplant</source>
<volume>17</volume>: <fpage>1964</fpage>&#x02013;<lpage>1970</lpage>.<pub-id pub-id-type="pmid">12401854</pub-id></mixed-citation></ref><ref id="pone.0041339-Schirmer1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Schirmer</surname><given-names>SH</given-names></name>, <name><surname>Fledderus</surname><given-names>JO</given-names></name>, <name><surname>van der Laan</surname><given-names>AM</given-names></name>, <name><surname>van der Pouw-Kraan</surname><given-names>TC</given-names></name>, <name><surname>Moerland</surname><given-names>PD</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Suppression of inflammatory signaling in monocytes from patients with coronary artery disease</article-title>. <source>J Mol Cell Cardiol</source>
<volume>46</volume>: <fpage>177</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">19059264</pub-id></mixed-citation></ref><ref id="pone.0041339-Strader1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Strader</surname><given-names>CD</given-names></name>, <name><surname>Fong</surname><given-names>TM</given-names></name>, <name><surname>Tota</surname><given-names>MR</given-names></name>, <name><surname>Underwood</surname><given-names>D</given-names></name>, <name><surname>Dixon</surname><given-names>RA</given-names></name> (<year>1994</year>) <article-title>Structure and function of G protein-coupled receptors</article-title>. <source>Annu Rev Biochem</source>
<volume>63</volume>: <fpage>101</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">7979235</pub-id></mixed-citation></ref><ref id="pone.0041339-Elenkov1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Elenkov</surname><given-names>IJ</given-names></name>, <name><surname>Wilder</surname><given-names>RL</given-names></name>, <name><surname>Chrousos</surname><given-names>GP</given-names></name>, <name><surname>Vizi</surname><given-names>ES</given-names></name> (<year>2000</year>) <article-title>The sympathetic nerve&#x02013;an integrative interface between two supersystems: the brain and the immune system</article-title>. <source>Pharmacol Rev</source>
<volume>52</volume>: <fpage>595</fpage>&#x02013;<lpage>638</lpage>.<pub-id pub-id-type="pmid">11121511</pub-id></mixed-citation></ref><ref id="pone.0041339-Jackson1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Jackson</surname><given-names>G</given-names></name>, <name><surname>Gibbs</surname><given-names>CR</given-names></name>, <name><surname>Davies</surname><given-names>MK</given-names></name>, <name><surname>Lip</surname><given-names>GY</given-names></name> (<year>2000</year>) <article-title>ABC of heart failure. Pathophysiology</article-title>. <source>BMJ</source>
<volume>320</volume>: <fpage>167</fpage>&#x02013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">10634740</pub-id></mixed-citation></ref><ref id="pone.0041339-Koomans1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Koomans</surname><given-names>HA</given-names></name>, <name><surname>Blankestijn</surname><given-names>PJ</given-names></name>, <name><surname>Joles</surname><given-names>JA</given-names></name> (<year>2004</year>) <article-title>Sympathetic hyperactivity in chronic renal failure: a wake-up call</article-title>. <source>J Am Soc Nephrol</source>
<volume>15</volume>: <fpage>524</fpage>&#x02013;<lpage>537</lpage>.<pub-id pub-id-type="pmid">14978154</pub-id></mixed-citation></ref><ref id="pone.0041339-Fraser1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Fraser</surname><given-names>J</given-names></name>, <name><surname>Nadeau</surname><given-names>J</given-names></name>, <name><surname>Robertson</surname><given-names>D</given-names></name>, <name><surname>Wood</surname><given-names>AJ</given-names></name> (<year>1981</year>) <article-title>Regulation of human leukocyte beta receptors by endogenous catecholamines: relationship of leukocyte beta receptor density to the cardiac sensitivity to isoproterenol</article-title>. <source>J Clin Invest</source>
<volume>67</volume>: <fpage>1777</fpage>&#x02013;<lpage>1784</lpage>.<pub-id pub-id-type="pmid">6263952</pub-id></mixed-citation></ref><ref id="pone.0041339-Bristow1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Bristow</surname><given-names>MR</given-names></name>, <name><surname>Ginsburg</surname><given-names>R</given-names></name>, <name><surname>Minobe</surname><given-names>W</given-names></name>, <name><surname>Cubicciotti</surname><given-names>RS</given-names></name>, <name><surname>Sageman</surname><given-names>WS</given-names></name>, <etal>et al</etal> (<year>1982</year>) <article-title>Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts</article-title>. <source>N Engl J Med</source>
<volume>307</volume>: <fpage>205</fpage>&#x02013;<lpage>211</lpage>.<pub-id pub-id-type="pmid">6283349</pub-id></mixed-citation></ref><ref id="pone.0041339-Brodde1"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Brodde</surname><given-names>OE</given-names></name>, <name><surname>Daul</surname><given-names>A</given-names></name> (<year>1986</year>) <article-title>Impaired regulation of alpha- and beta-adrenoceptor function in chronic renal insufficiency</article-title>. <source>Contrib Nephrol</source>
<volume>50</volume>: <fpage>28</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">3026728</pub-id></mixed-citation></ref><ref id="pone.0041339-Jie2"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Jie</surname><given-names>KE</given-names></name>, <name><surname>van der Putten</surname><given-names>K</given-names></name>, <name><surname>Bergevoet</surname><given-names>MW</given-names></name>, <name><surname>Doevendans</surname><given-names>PA</given-names></name>, <name><surname>Gaillard</surname><given-names>CA</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome</article-title>. <source>Heart</source>
<volume>97</volume>: <fpage>60</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">21071558</pub-id></mixed-citation></ref></ref-list></back></article>